Literature DB >> 31539155

The suppression of ox-LDL-induced inflammatory response and apoptosis of HUVEC by lncRNA XIAT knockdown via regulating miR-30c-5p/PTEN axis.

W-N Hu1, Z-Y Duan, Q Wang, D-H Zhou.   

Abstract

OBJECTIVE: Exposure of oxidized low-density lipoprotein (ox-LDL) could cause dysfunction of HUVEC, thus leading to atherosclerosis development, which is a common inflammatory vascular disease. Long noncoding RNA X-inactive specific transcript (XIST) has been reported to be implicated in atherosclerosis. However, the mechanism by which this lncRNA participates in the progression of atherosclerosis is poorly defined.
MATERIALS AND METHODS: HUVEC challenged by ox-LDL were used as a cellular model of atherosclerosis. Cell viability, apoptosis, LDH release, and inflammatory cytokines secretion were detected by MTT, flow cytometry, and ELISA assays. The expression levels of XIST, microRNA (miR)-30c-5p, and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) were measured by quantitative Real Time-Polymerase Chain Reaction and Western blot. The target interaction between XIST and miR-30c-5p or miR-30c-5p and PTEN was validated by the Luciferase reporter assay and RNA immunoprecipitation.
RESULTS: Treatment of ox-LDL induced cell apoptosis and inflammatory cytokines release in HUVEC. XIST expression was enhanced in HUVEC treated by ox-LDL, and its knockdown decreased cell apoptosis and inflammatory response in ox-LDL-treated cells. MiR-30c-5p was a target of XIST and its overexpression suppressed cell apoptosis and inflammatory response induced by ox-LDL, which was weakened by the introduction of XIST. PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression.
CONCLUSIONS: XIST knockdown suppresses inflammatory response and apoptosis of HUVEC stimulated by ox-LDL by increasing miR-30c-5p and decreasing PTEN.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31539155     DOI: 10.26355/eurrev_201909_18886

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression.

Authors:  Chong Wang; Lingling Li; Mengya Li; Weiqiong Wang; Yanfang Liu; Shujuan Wang
Journal:  Mol Med       Date:  2020-11-24       Impact factor: 6.354

2.  LncRNA-XIST Promotes Proliferation and Migration in ox-LDL Stimulated Vascular Smooth Muscle Cells through miR-539-5p/SPP1 Axis.

Authors:  Yi Zhang; Yong Tang; Jianhua Yan
Journal:  Oxid Med Cell Longev       Date:  2022-01-04       Impact factor: 6.543

3.  Myristicin regulates proliferation and apoptosis in oxidized low-density lipoprotein-stimulated human vascular smooth muscle cells and human umbilical vein endothelial cells by regulating the PI3K/Akt/NF-κB signalling pathway.

Authors:  Liang Luo; Huiying Liang; Luoying Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

4.  LncRNA XIST Promotes Atherosclerosis by Regulating miR-599/TLR4 Axis.

Authors:  Kechun Yang; Yun Xue; Xiaoya Gao
Journal:  Inflammation       Date:  2021-02-10       Impact factor: 4.092

Review 5.  Biological Function of Long Non-coding RNA (LncRNA) Xist.

Authors:  Wenlun Wang; Lu Min; Xinyuan Qiu; Xiaomin Wu; Chuanyang Liu; Jiaxin Ma; Dongyi Zhang; Lingyun Zhu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

6.  LncRNA SNHG12 regulates ox-LDL-induced endothelial cell injury by the miR-218-5p/IGF2 axis in atherosclerosis.

Authors:  Ping Mao; Xiaowei Liu; Yingzheng Wen; Lijiang Tang; Yimin Tang
Journal:  Cell Cycle       Date:  2021-07-27       Impact factor: 5.173

Review 7.  Regulatory Roles of Related Long Non-coding RNAs in the Process of Atherosclerosis.

Authors:  Qingyu Meng; Luya Pu; Xizi Luo; Baisen Wang; Fan Li; Bin Liu
Journal:  Front Physiol       Date:  2020-10-19       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.